The stem cell society's ethics committee is working on a paper that would explore the rights of tissue donors and make recommendations by the end of the year.

Some ethicists suggest that tissue donors deserve a share of the tremendous commercial potential of iPS cell lines as disease models, drug-testing platforms or treatments.

Also, the corneal donors are so rare as compared to the recipients, and the corneal tissue engineering progresses slowly, these conditions limit corneal transplantation.